Jury Cuts $100M From Award Against Wyeth

SANDRA CHEREB Associated Press Writer

(AP) - RENO, Nev.-A jury on Friday slashed $100 million from a compensatory judgment against pharmaceutical giant Wyeth after it conceded a previous award improperly included a levy to punish the company for its hormone replacement drugs.

Washoe District Judge Robert Perry instructed the five-man, two-woman jury to reconsider a $134.5 million award issued Wednesday after questions were raised about whether the judgment included punitive damages designed to punish the pharmaceutical maker.

<script language="Javascript" type="text/javascript">news230(); </script> <script language="Javascript1.1" src="http://ad.doubleclick.net/adj/fl.news.dart/;abr=!webtv;area1=news;area2=ap;area3=f;area4=66;area5=10-12-2007;level=4;pgnm=a95700102fa6269f;sz=300x250;ptile=2;ord=6411269020149969?" type="text/javascript"></script>

Perry said the matter was brought to his attention by a bailiff, who overheard discussion in the jury room.

After deliberating again for about three hours, jurors on Friday awarded a combined $35 million to the three Nevada women for past and future medical expenses, as well as physical and emotional pain and suffering.

The women claimed the company's hormone replacement drugs caused their breast cancer.

Jurors will return Monday to consider awarding punitive damages.

The judgment remains the largest award to date against the Madison, N.J.-based company, which faces about 5,300 similar lawsuits across the country in state and federal courts.

All involve the drugs Premarin, an estrogen replacement, and Prempro, a combination of estrogen and progestin. The drugs are prescribed to women to ease symptoms of menopause.

The panel deliberated for two days earlier this week before announcing its verdict in favor of Jeraldine Scofield, 74, of Fallon; Arlene Rowatt, 67, of Incline Village; and Pamela Forrester, 65, of Yerington.

During the trial, Wyeth lawyers argued that the drugs were safe and approved by the U.S. Food and Drug Administration. They also said information about possible risks is included with every prescription and provided to the women's doctors.

They also argued that the women had other risk factors, making it impossible to link their cancer to the hormone replacement drugs.